Methotrexate toxicity: Myths and facts;Methotrexat-Toxizität : Mythen und Fakten

Zeitschrift fur Rheumatologie

Volumn 70, Issue 2, 2011, Pages 108-113

  Keyer, G ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Basic therapy; Hepatic toxicity; Methotrexate; Pneumonitis; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION RISK; LIVER DISEASE; LONG TERM CARE; LUNG DISEASE; RHEUMATIC DISEASE; SIDE EFFECT; STANDARD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG-INDUCED LIVER INJURY; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; PNEUMONIA; RISK ASSESSMENT;

EID: 79952283262     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-010-0687-0     Document Type: Article

References (30)

1. Menninger H, Herborn G, Sander O et al (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060-1068
2. Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100-1104
3. Keysser M, Keysser G, Keysser C (1999) Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA). Z Rheumatol 58:267-276 (Pubitemid 29526614)
4. Choy EH, Smith C, Dore CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44:1414-1421 (Pubitemid 41631866)
5. Rau R, Schleusser B, Herborn G, Karger T (1998) Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 25:1485-1492 (Pubitemid 28364750)
6. Bernatsky S, Ehrmann FD (2008) Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging 25:879-884
7. Kent PD, Luthra HS, Michet C Jr (2004) Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 31:1727-1731 (Pubitemid 39202512)
8. Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30:101-108
9. Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54:3095-3103 (Pubitemid 44622078)
10. Wessels JA, Kooloos WM, De JR et al (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830-2839 (Pubitemid 44497761)
11. Rau R (2007) Nebenwirkungen. In: Rau R (Hrsg) Das Methotrexat-Buch - Aktuelle Therapiekonzepte in der Rheumatologie und Dermatologie, 1. Aufl. Uni-Med, Bremen, S 55-63
12. Ortiz Z, Shea B, Suarez-Almazor ME et al (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36-43 (Pubitemid 28060115)
13. Braun J, Kastner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73-81
14. Tilling L, Townsend S, David J (2006) Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 26:55-62 (Pubitemid 43275699)
15. Kocharla L, Taylor J, Weiler T et al (2009) Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 36:2813-2818
16. Verstappen SM, Bakker MF, Heurkens AH et al (2010) Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 69:1044-1048
17. Walker AM, Funch D, Dreyer NA et al (1993) Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36:329-335 (Pubitemid 23090599)
18. Hoekstra M, Ede AE van, Haagsma CJ et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423-426 (Pubitemid 36469732)
19. Kremer JM, Alarcon GS, Weinblatt ME et al (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40:1829-1837 (Pubitemid 27452534)
20. Belzunegui J, Intxausti JJ, De D Jr et al (2001) Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 19:727-730 (Pubitemid 34026840)
21. Dawson JK, Graham DR, Desmond J et al (2002) Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 41:262-267 (Pubitemid 34537861)
22. Karie S, Gandjbakhch F, Janus N et al (2008) Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47:350-354 (Pubitemid 351267205)
23. Yazici Y, Sokka T, Kautiainen H et al (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64:207-211 (Pubitemid 40193613)
24. Lim AY, Gaffney K, Scott DG (2005) Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford) 44:1051-1055 (Pubitemid 41487182)
25. Kalantzis A, Marshman Z, Falconer DT et al (2005) Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:52-62 (Pubitemid 40813391)
26. Kerstens PJ, Boerbooms AM, Jeurissen ME et al (1992) Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol 19:867-871
27. Veen MJ van der, HA van der, Kruize AA, Bijlsma JW (1994) Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53:224-228 (Pubitemid 24147188)
28. Pieringer H, Stuby U, Biesenbach G (2008) The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 27:1217-1220
29. Kapetanovic MC, Saxne T, Sjoholm A et al (2006) Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45:106-111 (Pubitemid 43033885)
30. Bourre-Tessier J, Haraoui B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 37:1416-1421